Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Connectasyl is a nutraceutical dietary supplement developed by Ghimas S.p.A., specifically formulated to support joint health and maintain the structural integrity of connective tissues. It is a combination product containing glucosamine sulfate, chondroitin sulfate, and ascorbic acid (Vitamin C). Glucosamine and chondroitin are essential structural components of articular cartilage that work synergistically to stimulate the synthesis of the extracellular matrix and inhibit degradative enzymes such as leukocyte elastase and hyaluronidase. Ascorbic acid serves as a vital cofactor for the enzymes prolyl and lysyl hydroxylase, which are necessary for the proper cross-linking and stabilization of collagen fibers. Connectasyl is primarily used as a supplement for individuals suffering from osteoarthritis or joint wear to improve mobility and reduce tissue degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Connectasyl.